To determine whether Tat vaccination could induce anti-Tat Abs capable of blocking Tat/Env entry and infection of MDDCs, sera from HIV infected HAART-treated patients from a phase II Tat therapeutic trial (ClinicalTrials.gov NCT00751595) [13] were tested prior to and after vaccination. This evidence concerns the gene DDX41 and infection.